_id
690db177ccc777a4e85d0bf7
Ticker
ASCLF
Name
Ascletis Pharma Inc
Exchange
PINK
Address
12/F, Building D, Hangzhou, China, 311200
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.ascletis.com
Description
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.
Last Close
1.55
Volume
5000
Current Price
1.775
Change
-0.02
Last Updated
2026-01-20T15:44:09.024Z
Image
-
Ipo Date
-
Market Cap
1750306688
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
1081000
Cost Of Revenue
960000
Gross Profit
121000
Operating Expenses
190114000
Operating Income
-189993000
Interest Expense
-
Pretax Income
-87951000
Net Income
-87951000
Eps
-0.09137547881972691
Dividends Per Share
-
Shares Outstanding
986088320
Income Tax Expense
-
EBITDA
-183676000
Operating Margin
-17575.670675300647
Total Other Income Expense Net
102042000
Cash
1580340000
Short Term Investments
199898000
Receivables
408000
Inventories
4822000
Total Current Assets
1822936000
Property Plant Equipment
51990000
Total Assets
1996835000
Payables
20000
Short Term Debt
3570000
Long Term Debt
-
Total Liabilities
128998000
Equity
1867837000
Bs_currency_symbol
CNY
Depreciation
9440000
Change In Working Capital
-
Cash From Operations
-172990000
Capital Expenditures
0
Cash From Investing
904605000
Cash From Financing
-14485000
Net Change In Cash
-
Cf_currency_symbol
-
PE
-
PB
0.9146827721048464
ROE
-4.70870852221045
ROA
-4.404520153142348
FCF
-172990000
Fcf Percent
-160.0277520814061
Piotroski FScore
0
Health Score
33
Deep Value Investing Score
6
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
4.5
Growth Investing Score
3
Momentum Investing Score
4.5
Net Net Investing Score
4.5
Quality Investing Score
2.5
Value Investing Score
5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
1081000
Quarters > 0 > income Statement > cost Of Revenue
960000
Quarters > 0 > income Statement > gross Profit
121000
Quarters > 0 > income Statement > operating Expenses
190114000
Quarters > 0 > income Statement > operating Income
-189993000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-87951000
Quarters > 0 > income Statement > net Income
-87951000
Quarters > 0 > income Statement > eps
-0.09137547881972691
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
962523000
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-183676000
Quarters > 0 > income Statement > operating Margin
-17575.670675300647
Quarters > 0 > income Statement > total Other Income Expense Net
102042000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
1580340000
Quarters > 0 > balance Sheet > short Term Investments
199898000
Quarters > 0 > balance Sheet > receivables
408000
Quarters > 0 > balance Sheet > inventories
4822000
Quarters > 0 > balance Sheet > total Current Assets
1822936000
Quarters > 0 > balance Sheet > property Plant Equipment
51990000
Quarters > 0 > balance Sheet > total Assets
1996835000
Quarters > 0 > balance Sheet > payables
20000
Quarters > 0 > balance Sheet > short Term Debt
3570000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
128998000
Quarters > 0 > balance Sheet > equity
1867837000
Quarters > 0 > balance Sheet > currency_symbol
CNY
Quarters > 0 > cash Flow > net Income
-87951000
Quarters > 0 > cash Flow > depreciation
9440000
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-172990000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
904605000
Quarters > 0 > cash Flow > cash From Financing
-14485000
Quarters > 0 > cash Flow > net Change In Cash
-
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.09137547881972691
Quarters > 0 > ratios > PB
0.9146827721048464
Quarters > 0 > ratios > ROE
-4.70870852221045
Quarters > 0 > ratios > ROA
-4.404520153142348
Quarters > 0 > ratios > FCF
-172990000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-160.0277520814061
Quarters > 0 > health Score
33
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
540500
Quarters > 1 > income Statement > cost Of Revenue
480000
Quarters > 1 > income Statement > gross Profit
60500
Quarters > 1 > income Statement > operating Expenses
95057000
Quarters > 1 > income Statement > operating Income
-94996500
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-43975500
Quarters > 1 > income Statement > net Income
-43975500
Quarters > 1 > income Statement > eps
-0.045687739409863454
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
962523000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-91838000
Quarters > 1 > income Statement > operating Margin
-17575.670675300647
Quarters > 1 > income Statement > total Other Income Expense Net
51021000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
1580340000
Quarters > 1 > balance Sheet > short Term Investments
199898000
Quarters > 1 > balance Sheet > receivables
408000
Quarters > 1 > balance Sheet > inventories
4822000
Quarters > 1 > balance Sheet > total Current Assets
1822936000
Quarters > 1 > balance Sheet > property Plant Equipment
51990000
Quarters > 1 > balance Sheet > total Assets
1996835000
Quarters > 1 > balance Sheet > payables
20000
Quarters > 1 > balance Sheet > short Term Debt
3570000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
128998000
Quarters > 1 > balance Sheet > equity
1867837000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-43975500
Quarters > 1 > cash Flow > depreciation
4720000
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-86495000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
452302500
Quarters > 1 > cash Flow > cash From Financing
-7242500
Quarters > 1 > cash Flow > net Change In Cash
-
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.045687739409863454
Quarters > 1 > ratios > PB
0.9146827721048464
Quarters > 1 > ratios > ROE
-2.354354261105225
Quarters > 1 > ratios > ROA
-2.202260076571174
Quarters > 1 > ratios > FCF
-86495000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-160.0277520814061
Quarters > 1 > health Score
33
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
1283000
Quarters > 2 > income Statement > cost Of Revenue
548000
Quarters > 2 > income Statement > gross Profit
735000
Quarters > 2 > income Statement > operating Expenses
296154000
Quarters > 2 > income Statement > operating Income
-295419000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-170618000
Quarters > 2 > income Statement > net Income
-170618000
Quarters > 2 > income Statement > eps
-0.17290634492935122
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
986765408
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-224538000
Quarters > 2 > income Statement > operating Margin
-23025.64302416212
Quarters > 2 > income Statement > total Other Income Expense Net
124801000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
865730000
Quarters > 2 > balance Sheet > short Term Investments
1081801000
Quarters > 2 > balance Sheet > receivables
5142000
Quarters > 2 > balance Sheet > inventories
4373000
Quarters > 2 > balance Sheet > total Current Assets
1970782000
Quarters > 2 > balance Sheet > property Plant Equipment
57204000
Quarters > 2 > balance Sheet > total Assets
2124572000
Quarters > 2 > balance Sheet > payables
31000
Quarters > 2 > balance Sheet > short Term Debt
6246000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
158410000
Quarters > 2 > balance Sheet > equity
1966162000
Quarters > 2 > balance Sheet > currency_symbol
CNY
Quarters > 2 > cash Flow > net Income
-170618000
Quarters > 2 > cash Flow > depreciation
10432000
Quarters > 2 > cash Flow > change In Working Capital
15993000
Quarters > 2 > cash Flow > cash From Operations
-138164000
Quarters > 2 > cash Flow > capital Expenditures
2095000
Quarters > 2 > cash Flow > cash From Investing
717273000
Quarters > 2 > cash Flow > cash From Financing
-58053000
Quarters > 2 > cash Flow > net Change In Cash
-
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.17290634492935122
Quarters > 2 > ratios > PB
0.8908261878726167
Quarters > 2 > ratios > ROE
-8.677718316191646
Quarters > 2 > ratios > ROA
-8.030699830365833
Quarters > 2 > ratios > FCF
-140259000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-109.32112236944661
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
641500
Quarters > 3 > income Statement > cost Of Revenue
274000
Quarters > 3 > income Statement > gross Profit
367500
Quarters > 3 > income Statement > operating Expenses
148077000
Quarters > 3 > income Statement > operating Income
-147709500
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-85309000
Quarters > 3 > income Statement > net Income
-85309000
Quarters > 3 > income Statement > eps
-0.08645317246467561
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
986765408
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-112269000
Quarters > 3 > income Statement > operating Margin
-23025.64302416212
Quarters > 3 > income Statement > total Other Income Expense Net
62400500
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
865730000
Quarters > 3 > balance Sheet > short Term Investments
1079426000
Quarters > 3 > balance Sheet > receivables
152000
Quarters > 3 > balance Sheet > inventories
4373000
Quarters > 3 > balance Sheet > total Current Assets
1970782000
Quarters > 3 > balance Sheet > property Plant Equipment
57074000
Quarters > 3 > balance Sheet > total Assets
2124572000
Quarters > 3 > balance Sheet > payables
31000
Quarters > 3 > balance Sheet > short Term Debt
6246000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
158410000
Quarters > 3 > balance Sheet > equity
1966162000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-85309000
Quarters > 3 > cash Flow > depreciation
5216000
Quarters > 3 > cash Flow > change In Working Capital
7996500
Quarters > 3 > cash Flow > cash From Operations
-69082000
Quarters > 3 > cash Flow > capital Expenditures
1047500
Quarters > 3 > cash Flow > cash From Investing
358636500
Quarters > 3 > cash Flow > cash From Financing
-29026500
Quarters > 3 > cash Flow > net Change In Cash
-
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.08645317246467561
Quarters > 3 > ratios > PB
0.8908261878726167
Quarters > 3 > ratios > ROE
-4.338859158095823
Quarters > 3 > ratios > ROA
-4.015349915182917
Quarters > 3 > ratios > FCF
-70129500
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-109.32112236944661
Quarters > 3 > health Score
34
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
1283000
Annuals > 0 > income Statement > cost Of Revenue
548000
Annuals > 0 > income Statement > gross Profit
735000
Annuals > 0 > income Statement > operating Expenses
296154000
Annuals > 0 > income Statement > operating Income
-295419000
Annuals > 0 > income Statement > interest Expense
244000
Annuals > 0 > income Statement > pretax Income
-300936000
Annuals > 0 > income Statement > net Income
-300936000
Annuals > 0 > income Statement > eps
-0.300458660124825
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
1001588704
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-390450000
Annuals > 0 > income Statement > operating Margin
-23025.64302416212
Annuals > 0 > income Statement > total Other Income Expense Net
-5517000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
865730000
Annuals > 0 > balance Sheet > short Term Investments
1081801000
Annuals > 0 > balance Sheet > receivables
5142000
Annuals > 0 > balance Sheet > inventories
4373000
Annuals > 0 > balance Sheet > total Current Assets
1970782000
Annuals > 0 > balance Sheet > property Plant Equipment
57204000
Annuals > 0 > balance Sheet > total Assets
2124572000
Annuals > 0 > balance Sheet > payables
31000
Annuals > 0 > balance Sheet > short Term Debt
6246000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
158410000
Annuals > 0 > balance Sheet > equity
1966162000
Annuals > 0 > balance Sheet > currency_symbol
CNY
Annuals > 0 > cash Flow > net Income
-300936000
Annuals > 0 > cash Flow > depreciation
20454000
Annuals > 0 > cash Flow > change In Working Capital
13787000
Annuals > 0 > cash Flow > cash From Operations
-341579000
Annuals > 0 > cash Flow > capital Expenditures
2148000
Annuals > 0 > cash Flow > cash From Investing
978906000
Annuals > 0 > cash Flow > cash From Financing
-103508000
Annuals > 0 > cash Flow > net Change In Cash
534209000
Annuals > 0 > cash Flow > currency_symbol
CNY
Annuals > 0 > ratios > PE
-0.300458660124825
Annuals > 0 > ratios > PB
0.9042082745979222
Annuals > 0 > ratios > ROE
-15.30575812166037
Annuals > 0 > ratios > ROA
-14.164547024059434
Annuals > 0 > ratios > FCF
-343727000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-267.908807482463
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
56596000
Annuals > 1 > income Statement > cost Of Revenue
30606000
Annuals > 1 > income Statement > gross Profit
25990000
Annuals > 1 > income Statement > operating Expenses
326198000
Annuals > 1 > income Statement > operating Income
-300208000
Annuals > 1 > income Statement > interest Expense
144000
Annuals > 1 > income Statement > pretax Income
-144715000
Annuals > 1 > income Statement > net Income
-144715000
Annuals > 1 > income Statement > eps
-0.13473096902601914
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
1074103460
Annuals > 1 > income Statement > income Tax Expense
95401000
Annuals > 1 > income Statement > EBITDA
-126091000
Annuals > 1 > income Statement > operating Margin
-530.4403138030956
Annuals > 1 > income Statement > total Other Income Expense Net
155493000
Annuals > 1 > income Statement > currency_symbol
CNY
Annuals > 1 > balance Sheet > cash
330117000
Annuals > 1 > balance Sheet > short Term Investments
1969286000
Annuals > 1 > balance Sheet > receivables
5432000
Annuals > 1 > balance Sheet > inventories
6071000
Annuals > 1 > balance Sheet > total Current Assets
2332756000
Annuals > 1 > balance Sheet > property Plant Equipment
68277000
Annuals > 1 > balance Sheet > total Assets
2491009000
Annuals > 1 > balance Sheet > payables
649000
Annuals > 1 > balance Sheet > short Term Debt
5710000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
148943000
Annuals > 1 > balance Sheet > equity
2342066000
Annuals > 1 > balance Sheet > currency_symbol
CNY
Annuals > 1 > cash Flow > net Income
-144715000
Annuals > 1 > cash Flow > depreciation
18480000
Annuals > 1 > cash Flow > change In Working Capital
38526000
Annuals > 1 > cash Flow > cash From Operations
-144162000
Annuals > 1 > cash Flow > capital Expenditures
19158000
Annuals > 1 > cash Flow > cash From Investing
149845000
Annuals > 1 > cash Flow > cash From Financing
-81496000
Annuals > 1 > cash Flow > net Change In Cash
-73651000
Annuals > 1 > cash Flow > currency_symbol
CNY
Annuals > 1 > ratios > PE
-0.13473096902601914
Annuals > 1 > ratios > PB
0.8140392463320846
Annuals > 1 > ratios > ROE
-6.17894628076237
Annuals > 1 > ratios > ROA
-5.809493261565896
Annuals > 1 > ratios > FCF
-163320000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-2.8857163050392254
Annuals > 1 > health Score
33
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
54090000
Annuals > 2 > income Statement > cost Of Revenue
78782000
Annuals > 2 > income Statement > gross Profit
-24692000
Annuals > 2 > income Statement > operating Expenses
319285999
Annuals > 2 > income Statement > operating Income
-343977999
Annuals > 2 > income Statement > interest Expense
157000
Annuals > 2 > income Statement > pretax Income
-314843000
Annuals > 2 > income Statement > net Income
-314843000
Annuals > 2 > income Statement > eps
-0.2896360099168938
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
1087029890
Annuals > 2 > income Statement > income Tax Expense
51869000
Annuals > 2 > income Statement > EBITDA
-284495000
Annuals > 2 > income Statement > operating Margin
-635.9364004437049
Annuals > 2 > income Statement > total Other Income Expense Net
29134999
Annuals > 2 > income Statement > currency_symbol
CNY
Annuals > 2 > balance Sheet > cash
2470834000
Annuals > 2 > balance Sheet > short Term Investments
2078266000
Annuals > 2 > balance Sheet > receivables
23873000
Annuals > 2 > balance Sheet > inventories
20519000
Annuals > 2 > balance Sheet > total Current Assets
2544726000
Annuals > 2 > balance Sheet > property Plant Equipment
73041000
Annuals > 2 > balance Sheet > total Assets
2657042000
Annuals > 2 > balance Sheet > payables
3135000
Annuals > 2 > balance Sheet > short Term Debt
2416000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
117156000
Annuals > 2 > balance Sheet > equity
2539886000
Annuals > 2 > balance Sheet > currency_symbol
CNY
Annuals > 2 > cash Flow > net Income
-314843000
Annuals > 2 > cash Flow > depreciation
30191000
Annuals > 2 > cash Flow > change In Working Capital
33807000
Annuals > 2 > cash Flow > cash From Operations
-142453000
Annuals > 2 > cash Flow > capital Expenditures
14401000
Annuals > 2 > cash Flow > cash From Investing
-1297387000
Annuals > 2 > cash Flow > cash From Financing
-1419000
Annuals > 2 > cash Flow > net Change In Cash
-1323643000
Annuals > 2 > cash Flow > currency_symbol
CNY
Annuals > 2 > ratios > PE
-0.2896360099168938
Annuals > 2 > ratios > PB
0.7596711249048185
Annuals > 2 > ratios > ROE
-12.395950054451262
Annuals > 2 > ratios > ROA
-11.849379874311358
Annuals > 2 > ratios > FCF
-156854000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-2.89987058606027
Annuals > 2 > health Score
33
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
76876000
Annuals > 3 > income Statement > cost Of Revenue
37703000
Annuals > 3 > income Statement > gross Profit
39173000
Annuals > 3 > income Statement > operating Expenses
264139000
Annuals > 3 > income Statement > operating Income
-224966000
Annuals > 3 > income Statement > interest Expense
125000
Annuals > 3 > income Statement > pretax Income
-199017000
Annuals > 3 > income Statement > net Income
-199017000
Annuals > 3 > income Statement > eps
-0.18131882257489337
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
1097608054
Annuals > 3 > income Statement > income Tax Expense
3121000
Annuals > 3 > income Statement > EBITDA
-169347000
Annuals > 3 > income Statement > operating Margin
-292.6348925542432
Annuals > 3 > income Statement > total Other Income Expense Net
25949000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
2495496000
Annuals > 3 > balance Sheet > short Term Investments
5200000
Annuals > 3 > balance Sheet > receivables
53606000
Annuals > 3 > balance Sheet > inventories
56233000
Annuals > 3 > balance Sheet > total Current Assets
2631551000
Annuals > 3 > balance Sheet > property Plant Equipment
77921000
Annuals > 3 > balance Sheet > total Assets
2829959000
Annuals > 3 > balance Sheet > payables
1054000
Annuals > 3 > balance Sheet > short Term Debt
1568000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
100887000
Annuals > 3 > balance Sheet > equity
2729072000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-199017000
Annuals > 3 > cash Flow > depreciation
29545000
Annuals > 3 > cash Flow > change In Working Capital
-10175000
Annuals > 3 > cash Flow > cash From Operations
-146930000
Annuals > 3 > cash Flow > capital Expenditures
7198000
Annuals > 3 > cash Flow > cash From Investing
-274492000
Annuals > 3 > cash Flow > cash From Financing
-31098000
Annuals > 3 > cash Flow > net Change In Cash
-483093000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-0.18131882257489337
Annuals > 3 > ratios > PB
0.7138889321534939
Annuals > 3 > ratios > ROE
-7.292478908581379
Annuals > 3 > ratios > ROA
-7.032504711198996
Annuals > 3 > ratios > FCF
-154128000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-2.004890993287892
Annuals > 3 > health Score
33
Valuation > metrics > PE
-0.09137547881972691
Valuation > metrics > PB
0.9146827721048464
Valuation > final Score
70
Valuation > verdict
8.5% Undervalued
Profitability > metrics > ROE
-4.70870852221045
Profitability > metrics > ROA
-4.824689402151255
Profitability > metrics > Net Margin
-81.36077705827937
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.06906277153734507
Risk > metrics > Interest Coverage
-1.9847793157482372
Risk > final Score
52
Risk > verdict
High
Liquidity > metrics > Current Ratio
507.7816155988858
Liquidity > metrics > Quick Ratio
506.4384401114206
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
52
Prev Risks > 1
38
Prev Risks > 2
38
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:25:08.524Z
Earnings History > 0 > period
2021-03-31
Earnings History > 0 > report Date
2021-06-30
Earnings History > 0 > date
2021-03-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
CNY
Earnings History > 0 > eps Actual
-0.0078
Earnings History > 0 > eps Estimate
0
Earnings History > 0 > eps Difference
-0.0078
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2020-12-31
Earnings History > 1 > report Date
2021-03-29
Earnings History > 1 > date
2020-12-31
Earnings History > 1 > before After Market
AfterMarket
Earnings History > 1 > currency
CNY
Earnings History > 1 > eps Actual
-0.0077
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-0.0077
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2020-09-30
Earnings History > 2 > report Date
2020-12-31
Earnings History > 2 > date
2020-09-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
CNY
Earnings History > 2 > eps Actual
-0.0116
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-0.0116
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2020-06-30
Earnings History > 3 > report Date
2020-08-28
Earnings History > 3 > date
2020-06-30
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
CNY
Earnings History > 3 > eps Actual
-0.0112
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
-0.0112
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2020-03-31
Earnings History > 4 > report Date
2020-06-30
Earnings History > 4 > date
2020-03-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
CNY
Earnings History > 4 > eps Actual
-0.0035
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
-0.0035
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2019-12-31
Earnings History > 5 > report Date
2020-03-23
Earnings History > 5 > date
2019-12-31
Earnings History > 5 > before After Market
AfterMarket
Earnings History > 5 > currency
CNY
Earnings History > 5 > eps Actual
-0.0035
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
-0.0035
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2019-09-30
Earnings History > 6 > report Date
2019-12-31
Earnings History > 6 > date
2019-09-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
CNY
Earnings History > 6 > eps Actual
-0.0033
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
-0.0033
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2019-06-30
Earnings History > 7 > report Date
2019-08-29
Earnings History > 7 > date
2019-06-30
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
CNY
Earnings History > 7 > eps Actual
-0.0032
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
-0.0032
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2019-03-31
Earnings History > 8 > report Date
2019-06-30
Earnings History > 8 > date
2019-03-31
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
CNY
Earnings History > 8 > eps Actual
-0.0033
Earnings History > 8 > eps Estimate
0
Earnings History > 8 > eps Difference
-0.0033
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2018-12-31
Earnings History > 9 > report Date
2019-03-24
Earnings History > 9 > date
2018-12-31
Earnings History > 9 > before After Market
BeforeMarket
Earnings History > 9 > currency
CNY
Earnings History > 9 > eps Actual
-0.0033
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
-0.0033
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2018-09-30
Earnings History > 10 > report Date
2018-12-31
Earnings History > 10 > date
2018-09-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
CNY
Earnings History > 10 > eps Actual
-0.0033
Earnings History > 10 > eps Estimate
0
Earnings History > 10 > eps Difference
-0.0033
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2018-06-30
Earnings History > 11 > report Date
2018-08-31
Earnings History > 11 > date
2018-06-30
Earnings History > 11 > before After Market
AfterMarket
Earnings History > 11 > currency
CNY
Earnings History > 11 > eps Actual
-0.0033
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
-0.0033
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2017-12-31
Earnings History > 12 > report Date
2018-03-31
Earnings History > 12 > date
2017-12-31
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
CNY
Earnings History > 12 > eps Actual
0.0042
Earnings History > 12 > eps Estimate
0
Earnings History > 12 > eps Difference
0.0042
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2017-09-30
Earnings History > 13 > report Date
2017-12-31
Earnings History > 13 > date
2017-09-30
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
CNY
Earnings History > 13 > eps Actual
-0.0076
Earnings History > 13 > eps Estimate
0
Earnings History > 13 > eps Difference
-0.0076
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2017-06-30
Earnings History > 14 > report Date
2017-09-30
Earnings History > 14 > date
2017-06-30
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
CNY
Earnings History > 14 > eps Actual
-0.0074
Earnings History > 14 > eps Estimate
0
Earnings History > 14 > eps Difference
-0.0074
Earnings History > 14 > surprise Percent
-
Earnings History > 15 > period
2017-03-31
Earnings History > 15 > report Date
2017-06-30
Earnings History > 15 > date
2017-03-31
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
CNY
Earnings History > 15 > eps Actual
-0.0027
Earnings History > 15 > eps Estimate
0
Earnings History > 15 > eps Difference
-0.0027
Earnings History > 15 > surprise Percent
-
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ASagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT) Seeking Alpha
Read more →(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Ascletis Pharma Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2021-03-31
EPS Actual
-0.0078
EPS Estimate
0
EPS Difference
-0.0078
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.